
Scientific Assessment & Selective Validation
We evaluate decision-critical scientific evidence and, where appropriate, use targeted validation to inform investment decisions.
Connecting scientific validation, drug development and global partnering to build investment value.
Explore Our ApproachProtheragen Capital is a science-led biopharma investment platform focused on innovative therapeutics and differentiated investment opportunities across the global biopharma ecosystem.
Our approach combines scientific expertise, drug development capabilities, and global industry insights to support informed investment decisions and long-term value creation. Through rigorous scientific assessment, targeted validation where appropriate, and milestone-oriented development strategies, we aim to identify and advance promising therapeutic innovations.
About Protheragen
Scientific rationale and therapeutic potential
Defined development goals and measurable progress
Opportunities for strategic partnering and value creation
We combine rigorous scientific assessment, milestone-focused development planning and global industry perspectives to inform investment decisions and support long-term asset value creation.

We evaluate decision-critical scientific evidence and, where appropriate, use targeted validation to inform investment decisions.

Development planning, specialist execution and staged capital allocation are aligned with defined evidence and budget milestones.

Industry and potential partner feedback help inform asset positioning and pathways to future financing, licensing or strategic transactions.
Our investment approach connects global asset sourcing, scientific assessment, selective validation, capital deployment, milestone-focused development and global partnering to support potential value realization. Experience and industry insights gained throughout the process help inform future investment decisions.
A selected investment reflecting our interest in innovative therapeutic approaches and long-term development potential.
RenaBio Therapeutics
Developing an in situ CAR-macrophage (CAR-M) platform using mRNA-LNP delivery to target multiple tumor-associated antigens in solid tumors, with initial programs in HCC and GBM.
Visit website →Through our scientific and industry relationships, we engage with biotech companies, researchers, investors and pharmaceutical partners to identify opportunities, assess development potential and explore strategic collaborations.


Protheragen Capital, a science-led biopharma investment platform, today announced its investment in RenaBio Therapeutics, Inc., a Greater Boston–based company developing in situ CAR-macrophage (CAR-M) therapy for solid tumors.
Read More →We welcome introductions from biotech founders, scientists and asset owners developing differentiated therapeutic innovations. Share a brief introduction, and our senior team will review your proposal and explore ways to support its development.
Submit Your OpportunityWe evaluate therapeutic opportunities based on four key dimensions:
Novel targets, mechanisms, or modalities.
Clear advantages over existing therapies.
Evidence supporting scientific feasibility.
Potential for development and partnerships.
Every proposal receives careful review. We welcome opportunities at all stages, from early concepts to advanced candidates.
A brief introduction to your company or program.
Initial assessment by our investment team.
In-depth scientific and development assessment.
Discussion of investment or partnership opportunities.
Connect with our team to discuss fund strategies and co-investment opportunities.
Submit non-confidential materials for rapid, rigorous evaluation by our investment team.
Direct all speaking invitations, panel requests, and press inquiries to our team.
For all inquiries, please contact us at
contact@protheragen.capital